AU2001233246A1 - Novel use of ribozymes to block gene expression - Google Patents

Novel use of ribozymes to block gene expression

Info

Publication number
AU2001233246A1
AU2001233246A1 AU2001233246A AU3324601A AU2001233246A1 AU 2001233246 A1 AU2001233246 A1 AU 2001233246A1 AU 2001233246 A AU2001233246 A AU 2001233246A AU 3324601 A AU3324601 A AU 3324601A AU 2001233246 A1 AU2001233246 A1 AU 2001233246A1
Authority
AU
Australia
Prior art keywords
ribozymes
gene expression
novel use
block gene
block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233246A
Inventor
Robert J Debs
Mohammed Kashani-Sabet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Pacific Medical Center Research Institute
Original Assignee
California Pacific Medical Center Research Institute
California Pacific Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Pacific Medical Center Research Institute, California Pacific Medical Center filed Critical California Pacific Medical Center Research Institute
Publication of AU2001233246A1 publication Critical patent/AU2001233246A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001233246A 2000-02-04 2001-02-02 Novel use of ribozymes to block gene expression Abandoned AU2001233246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18058600P 2000-02-04 2000-02-04
US60180586 2000-02-04
PCT/US2001/003406 WO2001057061A1 (en) 2000-02-04 2001-02-02 Novel use of ribozymes to block gene expression

Publications (1)

Publication Number Publication Date
AU2001233246A1 true AU2001233246A1 (en) 2001-08-14

Family

ID=22661001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233246A Abandoned AU2001233246A1 (en) 2000-02-04 2001-02-02 Novel use of ribozymes to block gene expression

Country Status (2)

Country Link
AU (1) AU2001233246A1 (en)
WO (1) WO2001057061A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416305A (en) * 2003-11-13 2007-01-09 Genentech Inc selection method, method of determining whether a mammalian patient diagnosed with cancer is likely to benefit from tgf-beta antagonist treatment, bone destruction or loss treatment method, mammalian patient treatment methods and kit comprising a container
JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド Humanized anti-TGF-β antibody
EP3542789A3 (en) * 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna

Also Published As

Publication number Publication date
WO2001057061A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2001291859A1 (en) Use of copolycarbonates
AU2001229712A1 (en) Reduction of hair growth
AU2001229493A1 (en) Antisense modulation of mekk2 expression
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2002224808A1 (en) Use of thienopyrimidines
AU2002253836A1 (en) Aptamer-mediated regulation of gene expression
AU2001285325A1 (en) Use of threo-methylphenidate compounds to enhance memory
AU2001237992A1 (en) Purification of oligonucleotides
AU2001266225A1 (en) Decondensation of dna
AU2002223648A1 (en) Personal cleansing composition
AU2002219988A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002217071A1 (en) Novel use of polyhydroxy compounds
AU2001297741A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2001265935A1 (en) Production of biohydrolysates
AU2001280436A1 (en) Process to increase protein stability
AU2001233246A1 (en) Novel use of ribozymes to block gene expression
AU2001261019A1 (en) Process and intermediates to prepare latanoprost
AU2002239409A1 (en) Compositions and methods relating to colon specific genes and proteins
AU2001241966A1 (en) Personal virtual assistant
AU2001272490A1 (en) Use of galiella lactone
AU2001297804A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
HK1053059A1 (en) New use of imidazotriazinon derivatives
AU2001286861A1 (en) Use of methylphenidate compounds to enhance memory